Study of Intravenous RXDX-107 in Patients With Solid Tumors

Summary

This is an open-label, Phase I/Ib, dose escalation study of intravenous RXDX-107 administered to subjects with advanced solid tumors. The study is designed to explore the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RXDX-107 and to define a recommended Phase 2 dose (RP2D)

Timeline

Start

2015-09

Primary completion

2016-09

Completion

2016-09

Outcome

Outcome not reported

Stopped: “Company decision”

Drugs

Indications